4th Quarter 2022
Key topics in this quarter’s edition include:
- Lecanemab and donanemab for Alzheimer’s disease
- Fezolinetant for vasomotor symptoms associated with menopause
- Pegcetacoplan for geographic atrophy secondary to age-related macular degeneration
- Roctavian (valoctocogene roxaparvovec) gene therapy for hemophilia A
Top